Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (3): 514-522    DOI: 10.31083/j.ceog.2021.03.2331
Special Issue: Obesity in pregnancy: risks and management
Original Research Previous articles | Next articles
Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy
Eun Jeong Choi1, Jung Yeol Han1, *()
1Department of Obstetrics and Gynecology, Inje University Ilsan Paik Hospital, Korean MotherSafe Counselling Centre, 10380 Goyang City, Korea
Download:  PDF(1096KB)  ( 65 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Backgrounds: To improve health, an increasing number of adults are attempting to lose weight. Moreover, the number of childbearing women targeting weight loss has increased, with a surge in pregnant women exposed to anti-obesity drugs. This study aimed to evaluate the ingredients, types, and trends of anti-obesity drugs and pregnancy outcomes among the exposures of anti-obesity drugs. Additionally, we reviewed their teratogenicity in literature. Methods: We performed a prospective cohort study and recruited pregnant women exposed to anti-obesity drugs in the Motherisk Database, from 2012 to 2018. We determined the frequency and type of anti-obesity drugs used. Furthermore, we compared the annual change in the frequency of anti-obesity drugs with that of total pregnancies. Overall, 30,704 pregnant women were enrolled during the study period. Results: The rate of pregnant women exposed to anti-obesity drugs was 4.8% (1487/30,704). The rate of pregnant women exposed to anti-obesity drugs significantly increased from 3.7% in 2012 to 7.4% in 2018 (p < 0.001). The most frequently used drugs were phentermine (33.0%) and phendimetrazine (25.9%). The number of pregnant women exposed to anti-obesity drugs has recently increased. There is no difference in pregnancy outcomes between the exposure and the un-exposure of anti-obesity drug except that birth weight and large for gestational age are significantly larger in the exposure group. Additionally, there are no difference of abnormalities between the exposure (3.1%) and the un-exposure of anti-obesity drugs (3.7%). Discussion: This study showed that the exposure of anti-obesity drug profoundly increased during the study period and there exist known teratogenic drugs. Therefore, childbearing women should be concerned with preventing teratogenic effects following anti-obesity drug exposure during pregnancy. Physicians should warn childbearing women about potential dangers of anti-obesity drug.
Key words:  Pregnancy      Anti-obesity drugs      Teratogen      Obesity      Overweight     
Submitted:  21 October 2020      Revised:  26 February 2021      Accepted:  05 March 2021      Published:  15 June 2021     
*Corresponding Author(s):  Jung Yeol Han     E-mail:  hanjungyeol055@gmail.com

Cite this article: 

Eun Jeong Choi, Jung Yeol Han. Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 514-522.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.03.2331     OR     https://ceog.imrpress.com/EN/Y2021/V48/I3/514

[1] Amanda M. Wang, Alan J. Lee, Shannon M. Clark. The effects of overweight and obesity on pregnancy-related morbidity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 999-1009.
[2] Leen Van den Eeden, Greet Leysens,Dominique Mannaerts, Yves Jacquemyn. Air pollution: cardiovascular and other negative effects on pregnancy: a narrative review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1010-1016.
[3] Xin Du, Qian Zou, Yu-Lan Liu. Transumbilical single-hole laparoscopic treatment of cesarean scar pregnancy by uterine artery pre-ligation: a report of 4 cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1044-1047.
[4] Marcelo Epsztein Kanczuk, Nicholas J Lightfoot, Alison Pighills, Antony Ji, Casey Steele, Daniel Bartlett. The time to perform spinal or general anaesthesia in COVID-19 positive parturients requiring emergency caesarean delivery: a prospective crossover simulation study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1099-1106.
[5] Noor Hazim Abdulkareem, Elham Hazeim Abdulkareem. SARS-CoV-2 detection in pregnant and non-pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1141-1145.
[6] Min Jung Kim, Hee-Sook Lim, Hae-Hyeog Lee, Tae-Hee Kim, Yongsoon Park. Dietary assessment, nutrition knowledge, and pregnancy outcome in high-risk pregnant Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1178-1185.
[7] Neha Sethi, Ann Gee Tan, Maherah Kamarudin, Sofiah Sulaiman. Successful delivery of a twin pregnancy with complete hydatidiform mole and coexistent live fetus: a case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1232-1247.
[8] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[9] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[10] Yu Deng, Zhan-Hui Ou, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Abraham Morse, Ling Sun. Age and anti-Műllerian hormone: prediction of cumulative pregnancy outcome in in vitro fertilization with diminished ovarian reserve[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 835-841.
[11] Serdar Balci. The effect of ultraviolet index measurements on levels of vitamin D andinflammatory markers in pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 888-892.
[12] Anna M. Rubinshtein, Oleg V. Golyanovskiy. Obstetric outcomes in women of advanced maternal age after assisted reproduction[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 893-900.
[13] Qian Hu, Mohammed Sharooq Paramboor, Tao Guo. Diagnosis and management of intramural ectopic pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 974-979.
[14] Alexandra Berezowsky, Howard Berger. Gestational weight gain and long-term postpartum weight retention[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 466-471.
[15] Ovadya Rosenbluh, Asnat Walfisch. Birth defects associated with obesity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 472-477.
No Suggested Reading articles found!